REG - Seed Innovations Ltd - Investee Company Update: Little Green Pharma Ltd

Seed InnovationsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250718:nRSR5707Ra&default-theme=true

RNS Number : 5707R  Seed Innovations Limited  18 July 2025

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

 

18 July 2025

SEED Innovations Limited

("SEED" or the "Company")

 

Investee Company Update: Little Green Pharma Ltd

 

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to
disruptive, high-growth, life sciences and technology ventures typically
inaccessible to everyday investors, is pleased to note that its portfolio
company, Little Green Pharma Ltd ("LGP"), has published its quarterly
activities report and Appendix 4C for the period ending 30 June 2025 on the
ASX.

 

SEED holds 7,324,796 ordinary shares in LGP, representing approximately 2.4%
of LGP's issued share capital.

 

Commenting on the announcement, Alfredo Pascual, Executive Director at SEED
said:

LGP has delivered another compelling quarter, achieving record cash receipts
of A$12.0 million and a turnaround to a positive net operating cash inflow of
A$0.5 million. This positive cash flow trend, combined with cash in bank of
A$2.5 million and over A$5.0 million in unused financing facilities, enhances
LGP's financial flexibility. We are particularly encouraged by the over 70%
increase in Danish facility sales into Germany and over A$2.0 million in new
UK purchase orders for FY26Q2 and Q3, which reinforce our confidence in LGP's
strategic focus and growth trajectory in key international markets."

 

The following excerpt from the announcement, which was released on the ASX, is
set out without any material changes.

 

Little Green Pharma Ltd

 

Quarterly Activities Report and Appendix 4C

 

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to
provide its activities report and Appendix 4C for the quarter ending 30 June
2025.

 

Highlights

·    Operating cashflow of $0.5 million resulting in an increase in total
cash of $0.15 million

·    Revenue of $9.1 million (unaudited) up over 20% on prior
corresponding period and cash receipts of $12.0 million up nearly 50% on prior
corresponding period

·    31 March 2025 full year financial statements completed with a clean
audit opinion; Revenue of $36.8 million (52% CAGR between FY22-FY25); Adjusted
EBITDA of $2.9 million; Net Profit after Tax of $3.3 million and Net Tangible
Assets of $0.24 per share

·    Danish facility sales into Germany up over 70% as German market
registers record imports of 37.2 tonnes

·    First LGP branded products launched in Germany under CherryCo line
New 2.4tpa room at Danish Facility commissioned giving a total capacity of
8.5tpa with another 2.4tpa room currently being fitted out

·    New laws facilitating Danish site to act as cannabis import, packing
and distribution hub effective 1 January 2026 with preparations underway

·    Cash in bank of $2.5 million, up from $2.4 million in prior quarter
with over $5.0 million in unused financing facilities

 

The announcement in full can be accessed via the following link:
https://investlittlegreenpharma.com/site/investor-centre/asx-announcements
(https://investlittlegreenpharma.com/site/investor-centre/asx-announcements?Archive=True&ArchiveMonth=7&ArchiveQuarter=Q3&Archive6Mths=H2&ArchiveYear=2025&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=2)

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation No. 596/2014, which forms part of United Kingdom domestic law by
virtue of the European Union (Withdrawal) Act 2018 (as amended).

 

 

- Ends -

 

For further information on the Company please visit: www.seedinnovations.co
(http://www.seedinnovations.co/)  or contact:

 

 Ed McDermott        SEED Innovations Ltd             E: info@seedinnovations.co 

 Lance de Jersey                                       
 James Biddle        Beaumont Cornish Limited,        T: (0)20 7628 3396

 Roland Cornish      Nomad                             
 Isabella Pierre     Shard Capital Partners LLP       T: (0)20 7186 9927

 Damon Heath         Broker
 Ana Ribeiro         St Brides Partners Ltd,          E: seed@stbridespartners.co.uk

 Isabel de Salis     Financial PR

 

NOTES

Seed Innovations Ltd

Seed Innovations Ltd is an AIM quoted investment company offering exposure to
disruptive, high-growth, life sciences and technology ventures typically
inaccessible to everyday investors. Its strategy focuses on identifying
early-stage opportunities with upcoming investment catalysts, alongside more
mature investments providing near-term liquidity. With a portfolio of such
investments and cash reserves, the Company is agile and poised to capitalise
swiftly on new investment opportunities.

 

Nominated Adviser Statement

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated
Adviser and is authorised and regulated in the United Kingdom by the Financial
Conduct Authority. Beaumont Cornish's responsibilities as the Company's
Nominated Adviser, including a responsibility to advise and guide the Company
on its responsibilities under the AIM Rules for Companies and AIM Rules for
Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont
Cornish is not acting for and will not be responsible to any other persons for
providing protections afforded to customers of Beaumont Cornish nor for
advising them in relation to the proposed arrangements described in the
announcement or any matter referred to in it.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUBGMUPAGMM